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Throenbolysis with recombinant lissue-type plasminogen activator
(rt-PA) and anisoylated ptasminagen streptoldnase activator
(APSAC) in myocardial infarction has been proved to reduce
mortally. Anew front-loaded infmtan regimen of 100mg of ri-PA
with an initial bolus dose of 15 mg followed by an infusion of 50 mg
over 30 min and 35 mg over 60 min has been reported to yield
higher potency rates than those achieved with standard regimens
of thrombolylic treatment
. The effects of this front-loaded admin-
istration of rt-PA versus those obtained with APSAC on early
latency and reocclusion of infarct-related coronary arteries zere
investigated in a randomized multicenter trial in 42! patients with
acute myocardial liffairction .
Coronary angiography 90 min after the start of treatment
revealed a patent infarct-related artery (Thromhotysis in Myncar-
dial reduction [TIM) grade 2 or
3) in 84.4% of 199 patients given
rt-PA versus 70.3% of 202 patients given APSAC (p = 0.0007) .
Early reocdusion within 2410 48 h was documented in 10 .3% of
174 patients given rt-PA versus 2 .5% of 163 patients given
APSAC. Late
within
24 days was observed in 2.6% of
Although the mechanisms by which throrabelytic therapy
reduces mortatity from acute myocardial idarclien are not
fully understood, early reperfusion is t houh.ht to be the mast
important factor . Several studies (1-10) en early patency of
the inforct-related coronary artery have shown potency rates
of 65% to
75% using various thrombolyti- agents and dose
regimens . Patency could not be improved by combinations
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152 patients given rt-PA versus 6
.3% of 159 patients given
APSAC .
There were 5 3o-hospital deaths ILA9b) in, the rt-PA
group
and
17 deaths (8
.1%) in the APSAC group (p = 0.60951 . The
reinfaretion rate was 3.8% and 4.8%, respectively, Peak serum
creatine kinase and left ventricular ejection fraction
at
fallow-up
angiography were essentially identical in belle treatment groups.
There were more bleeding complications after APSAC (45% vs .
31%, p = 0.0019). Two inlra racial hemorrhages (0.9%) oc.
curred in each diaup, one or these (in the APSAC group) was
fatal .
Front-loaded administration of 100 mg of ri-PA yicier a
significantly higher early patency rate of the infarct-related artery
In comparison with that achieved with APSAC . Although more
early reocclusions occur after rt-PA than after APSAC treatment,
hospital reinfarcUOn rates are similar . The statistically significant
difference in hospital mortality between the two patient groups
needs to be confirmed by a further trial with mortality as a
primary end poiul.
(d An Cog CardlnI 1992;19.SAf-9l)
of hbrinolytic agents Ill) . Higher patency rates were only
observed with large doses of rt-PA; however, these had lobe
abandoned because of an unacceptable risk of intracranial
hereon hage (12) .
Recently . a front-loaded dose regimen of
(00 mg of rt-PA has been reported 113) to yield an early
parrrncy rate >00% without an apparent increase in bleeding
risk. Because APSAC reportedly has the best early patedcy
rate of the nonhbrin-specific agents (6), we compared the
froni-loaded n-PA regimen with the standard halos injection
of APSAC in a randomized trial is patients with acute
myocardial infarction .
Methods
Study patients
. From March 1989 to rally 1990,4;5 pa-
tients aged 25 to75 years with an acute myocardial infarction
>30 min and <6 h in duration were enrolled into the study in
0773.1157719'355-101
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24 c!inicnl centers . Inclusion criteria were typical symptoms
of acute myocardial infarction and ST segment elevations in
at least 2 of the 12 leads of the standard electrocardiogram
(ECG): >2 mm in limb leads and >S nun in precordial leads
or > 1 moo in 2limb leads and ST segment depression >2 mm
in >2 precordial leads. Exclusion criteria were any of the
recognized contraindications to thrombolytic therapy (5),
any other condition posing an increased risk of bleeding
during fibrinolysis. u s judged by the physician in charge, and
inability of the patient to give informed consent . Further
exclusion criteria were previous infarction in the same site,
previous coronary artery bypass surgery and previous treat-
ment with streptokinase or APSAC
After informed consent . written or witnessed, was ob.
tained, the patient's identification Bras transmitted by phone
to the randomization center where the prepacked throm-
holytic agent to be given to that patient was determined . The
sample size of the study was C011 Dated to be 400 patients
(alpha = 5%, beta = 10p), assunli~lg 85% and 70% potency
efthe infarct-related artery 90 min
:dtertreatment with rt-PA
and APSAC, respectively. On fuiy 20, 1990, the trial was
terminated when 435 patients had been enrolled and more
than 400 patients had a 90-min aneriogram .
Treatment protocol and clinical investigations . Patients
randomized to n-PA received an intravenous bolus injection
of 5,000 U of heparin and a bolus dose of 15 mg of IT-PA,
followed by infusion of 50 mg over 30 min and 35 mg over
60 min . Patients randomized to APSAC received an intrave-
nous bolus injection of 5,000 U of heparin followed by a
bolus dose of 30 mg of APSAC injected over 5 min . During
infusion of n-PA or after injection of APSAC the patients
were transferred to the cardiac catheterization laboratory .
Tie first angiogram of the presurned infarct-refuted ar-
tery was performed in at least two orthogonal projections
60 min after the start of fibrinolytic therapy . Subsequently
the remaining coronary arteries were filmed in at least two
projections for the right and three standard projections for
the left coronary artery . Ninety minutes alter the onset of
fibriootysis a second angiogram of the infarct-related artery
was again obtained in the same projections as after 60 min-
After the 90-min angiogram the investigators were
free to
perform further recanali7ation procedures, but they were
asked to do so only in case of poor perfusion (Thrombolysis
in Myocardial Infarction ITIMII grade 0 or 1) . The intro-
ducer sheaths were left in place for an additional angiogram
of the infarct-related artery, which was obtained after 24 to
48 h . At the end of the hospital stay (14 to 21 days) coronary
angingrnphy and left ventrtculogrephy were repeated unless
clinically contraindicated . A 12-lead ECG was recorded
before treatment, after 4 and 24 h and before hospital
discharge- Creatine kinase ME fraction jCK MB) serum
levels were measured before treatment and at 4-h intervals
up to 48 h . Fibrinogen levels were measured before treat-
ment and after 4 and 24 h
. Anticoagulation with intravenous
heparin was begun immediately after fibrinolysis in the n-PA
treatment group and 6 h after administration of APSAC,
when the thrombin time had returned below 2.5 times normal
or the partial thrombin time below 1
.5 times normal values .
Anticoagulation was maintained throughout the hospital stay
either by intravenous or subcutaneous heparin or by an oral
entf^_oagulnnt agent . In addition, 100 mg of aspirin was given
daily during the hospital stay.
The secondary endpoint of reinfarction was defined
as an
anginal episode of >30-min duration associated with a sig
ni0cant increase in cardiac enzymes (more than twice the
normal level) or significant newly developed Q waves in the
ECG, or both .
Assessment ofcoronaryandventricnlarangiograms. Each
angiogram was centrally graded for potency and perfusion of
the infarct-related coronary artery independently by two
experienced investigators (K .-L .N . and R .v .E .) according to
the classification of the TIMI study group (3) . Any discrep-
ancies in coronary angiogrophic interpretations were re-
solved by a consensus committee (K,- L .N ., E,v .E„ U.T .) .
The investigators were unaware of the treatment group
. Left
ventricular ott kgrams (30" right anterior oblique projection)
were analyzed for ejection fraction with the formula of
Sandler rind Dodge (14).
Statistical analysis . The proportion of events in the two
treatment groups was compared with chi-square or r tests .
The chi-square test was corrected according to Yates, when
the number of events was <5 in at least one cell . Values are
presented as mean values t SD.
Results
Baseline data (Table 1). A total of 43S patients were
randomized to treatment with n-PA (n = 217) or APSAC
(n = 218) . After randomization, 14 patients did not receive
thrombolytic therapy because of detection of a contraindi-
cation, spontaneous normalization of the ECG or withdrawal
Table 1 . Setected Baseline Variables in the Two
Treatment Groups
JACC v.a 19 .N,, .5
April 1552o88-L91
'Mean valves a ND, APSAC = s,m6ylvted plasminogcn slreptokinase
aetivetor: Ml = my-dial infmcuel,, n-PA = rernmhimrol ossue-type
plasnunogen acsvamr
.
n-PA
In = 217)
AI•SAC
to = 216)
Men 1901 84 .7 77.9
Age (yrr' 56 .6 5 to 57.2 e 9
Systolic blood onetime toast Hg)' 136 , 25 133' 25
Outtalk blood pressure (mm H5)' 82 { 13 a2 ± 14
Hear) rare (bea(smin)' 79 a IS 76-_ 16
.Anlenor Ml ins) 9914) 93173+)
Prcuiouc Ml lnal 23 (11%) 25 (124)
Time from until orsymptums to
infusion (10O
Palienls reined wil)
;n
2
.6 o 1 2 2 .5 1 .1
0-2 h 67 (3251 65(31%)
>2-4 h 106(51%1
132190001
>4-6 h 36 (1751
23 (1194
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Table 2. Potency of infarct-Related Artery in 421 Patients
TIMI= Thrombolysis in Myocardiall005001 2 01herahbresiat:ttsasIn
Table I .
of consent. In 2 of these 14 patients no data could be
obtained : in the remaining 12 there were no deaths or other
significant adverse events, Six of these patients had been
allocated to each treatment group . Thrombolysis was per-
formed according to the study protocol in 421 patients; 210
were treated with rt-PA and 211 with APSAC .
With respect to baseline variables, there were no statis-
tically significant differences between the treatment groups ;
concomitant treatment included intravenous nitroglycerin in
77% and 75500 of the patients in She R-PA and APSAC
groups, respectively . However, there were more men in the
rt-PA group (84
.7% vs . 77.9,3, p = 0 .0678).
Angiographie findings : patency rates (Table 2) . The 90-
min angiogmm (performed 61 = 4 min after rt-PA and 60
8 min after APSAC) was obtained, respectively, iT 94 .7%
and 97.2% of patients ; the 90-min angiogram was olrained at
a mean of 91 ± 3 min after rt-PA. in 95 .2% and at 91 ± 4 min
after APSAC in 96.2%. Follow-up angiograms were per-
formed after 24 to 48 h in 95 .2% and 93 .3% , respectively, and
after 14 to 21 days in 85.6% and P4.4% . respectively, of the
patients treated with rt-PA or APSAC. The patcncy
:aces at
60 and 90 min from treatment onset were substantially higher
with rt-PA . After 24 to 49 h, however, the patency rate was
sigtiScantiy higher in the APSAC group . After 14 to 21 days,
the patcncy rates were similar in both groups . Left ventric-
ular angiograms aaitabie for interpretation were available
from 146 and 145 patients at 14 to 21 days after treatment
with rt-PA and APSAC, respectively . The left ventricular
ejection fraction was 57 = 1370 and 57 = 10%, respectively .
The patency rate of the infarct-related artery was not influ-
ereed by patient body weight in the n-PA group but was
decreased in the APSAC group (Fig. 11.
Interventions . Addilionalrecanalizalion procedures were
performed in a
total of 46 patients treated with n-PA and 58
patients treated with APSAC. Overall success moos write
73 .9% and 70 .7%. respectively. Earl) interventions immedi-
ately after the 90-min angiogram were performed more often
NEURADS ET AL .
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Fgnre 1. Potency tale a) 00 min and body weight in patients ,rented
00th recombinant tissue-type plasminogen activator (n-PA) or an-
iseylated plasminogen streptosinase activator IAPSAC. The pro-
portion of ratients with a minus infesct-related artery, (Thrombolysis
in Myacmdial Infarction ITIMI' grade 2 or 31 was not influenced by
body weight in the r;-PA group but decreased with increased weight
in the APSAC group . Figureswithin columns indicate the numberof
patients in limo respective-right groups .
in the APSAC group (47 vs . 26) ; coronary angioplasty was
the procedure most often performed (26 in the APSAC group
vs . 19 in the rt-PA group). Coronary bypass surgery was
performed in four patients treated with rt-PA and in one
patient treated with APSAC .
Reoceltson of the infarct-related artery (Table 3) . The
infarct-related coronary artery was patent at completion of
the 90-min coronary angiogram, with or without additional
recanalizatien procedures, in 179 of the 210 patients treated
Table 3. P,aorelusion Rates of Patent Infarct-Related Artery
Parent annoy 1TIMt grade 2 or 31
409, 515* angiogaphw swdy,
indnding suanniol
Aefudad,dar'--4a,48h
(ITMI grade o rn 4)
Noawinrrnnt
211043 h
Reurdwkd alter
14 to 21
days glade ITIMI glade 0
or 1)
veat
ara:ry 171 .11 grade 2 or 3)
v9Qmlcav yo~an,- ailha,u
.rdmnunm erenem/er
Reocdnded A 241o 48 h
ITIMI grade 0 or 1)
No angi0gram al 3 3
241.48 h
Crow, :40 711er14to21days 4.941 91130 0.1186
1T3M1 grade 0 a 11 12.0`91 169°.)1
S ix palien+a mld3n tot mmnar
y angioplaaly despite TIM] grade 2 nr 3
P.fusnn at 90 u :.
IN.
patients ondnwenl coronary ongioplnsry despite
TIM] grade : or 3 petauaa a 90 min . AEb ,-Ann ns as in Tabks I and 2.
R-PA
In = 210)
APSAC
In = 3111
p value
1y msrr
Argiograrn N 40 in In. i 199 '-04
TIMI grade 2 or 1 73 4%. 60772 000_23
TtM1 grade 3 54 8E 40764 0.0034
Ao8i41am .1 93 m6 1no.l 199 1 02
TIMI araer 2 or) 88,1)5 70,3% 0.0007
TIM grade 3 72 9",7 54,0 0,01/01
Andagram at =' :046 h 110.1 (9) 196
TIMI grade : or 3 14,9',7 01 .t2 2 .0268
TIM1gr.de3 71 .970 80.12) 0 .2455
Antic'- or 14 m 21 day, 177 174
(n0 .1
88.749 90.7`0 0.6916TIM: grade 7 or 3
TIM Igrade3 83.22) 87.8.0 0,3013
n-PA APSAC
p Value
(0ttau
179299 16&202 0.0466
(69 .93) (83.2`)5)
181174 4,163 0 .0034
(10 .3%) (2.5%)
a 5
4)152 100159 0.1228
12 .0
.31
(6
.391)
133)2025 O.OLM
(81 .4%) (65 .8%)
151159 01130
Room
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Table 4 . Cardiac and Other Events After the Stann of
Thrombolytic Trcatmcm
*As reported by the local investigators . Data are presented as number and
percent of putienls . BP = blood pressure .
with rt-PA compared with 168 of the 211 patients treated
with APSAC . A repeat angiogram after 24 to 48 h was
obtained in 176 patients treated with rt-PA and 163 treated
with APSAC who had a patent artery after the first angio-
gram . Reocclusion was found in 18 patients (10.3%) after
rt-PA and in 4 patients (2 .5%) after APSAC ; predischarge
angiography showed a late reoccluston in 4 (2.6%) and 10
(6 .2%) patients, respectively . The corresponding figures for
patients without a coronary intervention in addition to
thrombolysis are depicted in Table 3
. No patient in the
APSAC group had early reocclusioa compared with 15
patients (9
.4%) in the rt-PA group . However, late reocclu-
sion was seen more often in the APSAC group.
Cardiac events (Table 4). Six of the 8 reinfarctions in the
rt-PA group and I of the 10 in the APSAC group occurred
during the 1st 48 h
. Recurrent ischemia (new ST segment
elevation and angina pectoris) was seen in seven patients
treated with n-PA (within the 1st 48 h in all) and in
six
APSAC-treated patients (early in three) . A decrease in blood
pressure, cardiogenic shock and allergic reactions was seen
more frequently in the APSAC group
.
Bleeding events. These events were also observed signif-
icantly more often in the APSAC-treated patients . There was
one retroperitoneal hematoma in the rt-PA group and then :
were two, one of which was lethal, in the APSAC group
.
Cerebrovascular accidents were seen in throe patients
treated with rt-PA and in four treated with APSAC . Two of
these in each group were cerebral bleedings documented by
computed tomography
. One of these
patients
in the APSAC
group died within the Ist 48 h
.
Mortality . The overall hospital mortality was 22 (5
.1%) in
the 433 patients . Nineteen patients died from cardiac causes,
JACC Vet . 19. No. 5
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one from cerebral bleeding and one from diffuse intractable
bleeding, both of the latter after APSAC . Mortality was
significantly different between the two groups : 5 (2 .4%)
versus 17 (8.1%) patients died in the rt-PA and APSAC-
treated groups, respectively (p = 0 .0095) . Two of the five
patients in the rt-PA group and 10 of the 17 in the APSAC
group had an occluded infarct-related artery after 90 min .
Reocclusion of the infarct-related artery was observed in
another patient in the rt-PA group and in four other patients
who died in the APSAC group. In two of them, coronary
angioplasty was angiographically successful .
Laboratory findings. Peak creatine kinase was 1,052 =
855 Ulliter in the rl-PA group and 1,048 ± 789 Ulliter in the
APSAC group. Fibrinogen levels were 3 .3 3 I (rt-PA) and
3 .2 30 I (APSAC) glliter before treatment
; they decreased to
2.1 = 1 .1 and 1 .2 m 1 .3 g/liter (p = 0 .0001), respectively,
after 4 h . Mean hemoglobin concentrations before treatment
were 14.4 ± 2 .1 (rt-PA) and 14.3 ± 2 .1 (APSAC) g/dl ; they
decreased to 13.2 ± 2 and 12.7 ± 2 .2 g/dl, respectively, after
24h(p=0.010).
Discussion
rt-PA vs, APSAC. Thrombolytic therapy of acute myo-
cardial infarction has been shown to reduce mortality signif-
icantly regardless of the Thrombolytic agent tested (15-22).
The relative efficacy of different fibrinolytic agents should be
judged primarily by the speed and completeness of throm-
bolysis and, hence, repeefusion
of the ischemic myocardium.
An accelerated infusion regimen of rt-PA (aiteplase) was
recently reported to be more effective with regard to early
coronary potency than other fibrinolytic agents tested so far
(13). In the present prospective randomized patency study,
this front-loaded infusion of rt-PA was compared with the
standard dose of APSAC. APSAC was chosen as the refer-
ence thrombolytic agent because it reportedly provides air
early potency rate of about 70%, a low reocclusion rate and
a substantial reduction of in-hospital mortality, the latter two
being secondary end points of this trial .
Patency of the infarct-related artery . Early patency of the
infarct-related coronary artery, the main end point of the
trial, was substantially higher with it-PA than with APSAC
(84 .4% vs
. 70,3% at 90 min after treatment onset, p =
0 .0007). These figures exactly fulfilled the assumptions un-
derlying the sample size calculation . Prompt distal filling
(TIM I grade 3) of the infarct-related artery indicating cam-
plete reperfusion was also seen in significantly more patients
treated with rt-PA (71.9% vs . 54%, p = 0.0002)
. The in,
creased speed of thrombolysis with the front-loaded rl-PA
infusion was also reflected by the significantly higher pa-
tency rate 60 min after treatment onset (73 .4% vs. 60 .3%,
p = 0.0053), This is superior to potency data reported so far
for any other thrombolytic agent in standard dosages, and
approaches the overall early,atency achieved by combined
thrombolytic treatment and mechanical coronary interven-
tions (23-25) .
,t-PA
0, = 210)
APSAC
(a = 211)
p Va . .
(c° eat)
Reinfarction
80 .8%)
10 )4 .85s) 0.6528
Recurrent ischemia 7 (33%)
6 )2
.9%) 0.7590
BP decrease <90 mm Hg
0 to 90 min 22 00%) 38 08%) 0.0298
90 min 1o 48 h 25 112%) 31 (15%) 0.4263
Cardiogcnic shock
0 to 90 min 0 1 (I
.9%)
0.0459
W3 min to 48 h 4 11 .0%) 13 10 .2%) u.u278
Allergic rcaotion o to 24 h- 1 (ns%) Is )8 .6%) test
Bleeding
Overall 65131%) 96(45%) OA019
Panatoresae 3205%) 63(30%) 0.0004
Trans .,ioa
6(2 .8%) n IS
. 1n)
0.0201
Cerebral 2 (4 .9%1 2 f3 .9%) 1 .0000
Cerebrovaecular ischemia
1 (0 .5%) 2 (0 .9%) 0.5719
Pericardial tampooade 1 (0 .5%) 3 ) .4 50! 0.3240
lo-ho,piml d,eth 5 (2 .4%) 171c.1%l 0.0095
0 to 48 I' 2 (0 .9%) 9 (4.3%) 0.0344
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The patency rates achieved with APSAC in the present
study are well within the range observed in several smaller
angiographic studies (6-8) The accelerated infusion of the
standard dose of 100 mg of rt-PA clearly exceed,, the
formerly assumed "ceiling" of 75% early patency (231 .
Weight-adjusted dosage of fibrinolytic agents has been
claimed to be especially important for rt •PA 126) . In the
present study, however., the effect of body weight on early
patency was clearly more important for APSAC treatment,
whereas overall pateney after rt-PA treatment was unaf-
fected by body weight )Pig- t) .
Reoeelusion of infarct-related artery . A problem that re-
mains unresolved is reocciusiuovt eftar infarct-related curu-
nary artery after successful thrombolysis
. This occurs in
spite of strict anticoagulation with heparin and aspirin more
often after rat-PA than after .APSAC treatment, at least during
the first days alter thrombolysi, (5 .27)
.
In
the pre ent mat,
early reocclusion as assessed by repeat angiography after 24
to 48 h (performed in 94.3% of treated patients) was docu-
mented in 10 .3% vs- 2 .5% of patients treated with rt-PA and
APSAC, respectively Ip = 0 .0034) . When patients with
additional coronary interventions, which might interfere
with reocclusion, were excluded from the analysis, the
respective early reocclusion rates were 9.4% and 0% (p =
0.0003).
A similar difference had been shown in the German
Activator Urokinase Study IGAUSI trial (5) comparing
rt-PA and urokinase . and the Thrombolysis and Angioplasty
in Myocardial Infarction (TAM]) trial (11) comparing rt-PA
with a combination of rt-PA and urokinase . The reocclusion
rate after the front-loaded rt-PA treatment was in the same
range as that reported previously for treatment with rt-PA
(5,13) .
It must be taken into account that more patients in the
ri-PA group had a patent artery after treatment ; therefore
more arteries in this group were susceptible to reocclusion .
On the other hand, more patients in the APSAC group (35
vs. 16) had a successful intervention after unsuccessful
lhrombulysis. These fu-l-, together with the higher pro-
portion of coronary arteries recanalized later than 90 min (15
vs . 5 patients, "catch-up" phenomenon) alter APSAC treat-
ment, increased the pateney rate at 24 to 48 h to 93.4%
compared with 84.9% in the rt-PA group (p = 0-0268). Late
reocclusion were detected by predischarge angiography in
more patients treated with APSAC (6.4% vs . 2.6%, p =
0.1228), accounting for a total of 22 reocclusion (early plus
late) in the rat-PA and 14 in the APSAC group. This differ-
ence, however, does not translate into the total number of
related clinical events ; rcinfarction and recurrent ischemia
were evenly distributed in both treatment groups (Table 4)
but Occurred more often within the Isl 2 days after rat-PA
treatment.
Crirfcal events. Although there was no difference in he-
modynamic status on admission or in the incidence of
previous or acute anterior myocardial infarction between the
groups, hypertension during the 1 s190 min (I8% APSAC vs .
NSUHAUS ET AL .
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143% rt-PAI, cardiogenic shock within 24 h (5% vs . 2%) and
allergic reactions (35% vs . 0.5%) developed more often in
the APSAC group- Hemorrhage at the arterial poncmre site,
the most frequent severe bleeding complication, occurred
twice as
aft-:n
after APSAC treatment (63 vs . 32 patients ; 17
vs. 6 of t'tese required transfusion)- This high rate of
bleeding as compared with that in
most
other trials may he
attributed n part to the ooneomitaat treatment with aspirin
and hepar. t- especially in the APSAC-treated patients, who
may not s quire heparin for thromholysis . The incidence of
cerebrova cular events was the same in both treatment
group,- at d similar to that of earlier reports (17,19-22)- The
nsk of life-threatening bleeding complications does not seem
to be increased with the front-loaded in-PA infusion, as can
he assess -d from almost 300 patients now reported .
Mortality. The hospital mortality rate was significantly
tower in the rt-PA group (2 .4% vs, 0 .1%, p = 0 .0095). The
mortality rate in the APSAC-recated patients was within the
range of that in several large trials that have reported a
haspilnl mortality rate of 6.5% to 9% after ehromholytic
therapy with streptokinase (19,20), APSAC (17,18) ar rat-PA
115 •[ 6). An in-hospital mortality rate as low as that in iite
present study was reported for rt-PA-treated patients by the
European Cooperative Study Group (28)-
However, in that
study . left ventricular function was a primary end point and
the placebo group had an unusually low mortality rate of
5 .4% . Therefore, the front-loaded rat-PA regimen may im-
prove early survival, probably by reducing the rate of failed
early reperfusion to about 50% of the rate associated with
conventional thrombolytic treatment . This hypothesis is
supported by the fad that 14 of 17 deaths occurred in
patients in the APSAC group who had no early reperfusion
(10 patients) or had early reocclusion of the infarct-related
artery (4 patients). In the rat-PA group, three of five deaths
occurred after unsuccessful thrombolysis or reocclusion.
to contrast to mortality, left ventricular function as as-
sessed from predischarge ventriculography was essentially
the same 'n both treatment groups . This discrepancy may he
explained in part by the fact that nunsurvivorn with presum-
ably poor ventricular function had no predischarge angio-
gram. Moreover, ventricular function has been claimed to be
dependent on sustained potency, whereas short-term sur-
vival at least in the present study is associated with an
improved early patency of the infarct-relined artery . There-
fore, early and sustained patency seem to be of major
importance for a favorable outcome,
Cumlusions. The front-loaded infusion of 100 mg of
rt-PA in 90 min reduces the frequency of failed thrombolysis
by about '0% without an increase in rocclusion or bleeding
risks as compared with resuhs of the standard administration
over 3 h . Compared to APSAC treatment, despite more early
reocclusion the clinical course with rt-PA treatment is more
favorable with fewer bleeding complic'-lions and n subsmn-
Iially lower in-hospital mortality ate . presumably due to
improved early patency of the infarct-related artery . This
improved survival with from-loaded rt-PA treatment has to
890
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be regarded as an observational finding that needs to be
substantiated by larger mortality trials .
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